Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jagadeesh Aluri

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Pharmacology Research & Perspectives|March 10, 2021
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|November 2, 2020
Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|April 6, 2021
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexantSatish Dayal, Jagadeesh Aluri, Nancy Hall, et al.
Clinical Drug Investigation|July 16, 2014
Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adultsRobert C Shumaker, Jagadeesh Aluri, Jean Fan, et al.
Clinical Pharmacology in Drug Development|June 9, 2021
Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy FemalesIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Clinical Therapeutics|March 15, 2011
Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjectsDavid John Critchley, Jagadeesh Aluri, Peter Boyd, et al.
Clinical Pharmacology in Drug Development|May 30, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy AdultsIshani Landry, Kenya Nakai, Jim Ferry, et al.
Cancer Chemotherapy and Pharmacology|March 25, 2014
Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteersRobert C Shumaker, Meijian Zhou, Min Ren, et al.
Journal of Psychopharmacology (Oxford, England)|May 31, 2022
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover studyIshani Landry, Nancy Hall, Jagadeesh Aluri, et al.
Journal of Clinical Psychopharmacology|June 24, 2022
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative UsersIshani Landry, Nancy Hall, Jagadeesh Aluri, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Pharmacology Research & Perspectives|March 10, 2021
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|November 2, 2020
Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|April 6, 2021
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexantSatish Dayal, Jagadeesh Aluri, Nancy Hall, et al.
Clinical Drug Investigation|July 16, 2014
Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adultsRobert C Shumaker, Jagadeesh Aluri, Jean Fan, et al.
Clinical Pharmacology in Drug Development|June 9, 2021
Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy FemalesIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Clinical Therapeutics|March 15, 2011
Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjectsDavid John Critchley, Jagadeesh Aluri, Peter Boyd, et al.
Clinical Pharmacology in Drug Development|May 30, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy AdultsIshani Landry, Kenya Nakai, Jim Ferry, et al.
Cancer Chemotherapy and Pharmacology|March 25, 2014
Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteersRobert C Shumaker, Meijian Zhou, Min Ren, et al.
Journal of Psychopharmacology (Oxford, England)|May 31, 2022
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover studyIshani Landry, Nancy Hall, Jagadeesh Aluri, et al.
Journal of Clinical Psychopharmacology|June 24, 2022
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative UsersIshani Landry, Nancy Hall, Jagadeesh Aluri, et al.
Pageof 4